

[Subscribe](#)[Past Issues](#)[Translate](#) ▼[RSS](#) 📡

Vasalgel Update

ANNOUNCEMENT: This is the last update on Vasalgel that the Parsemus Foundation will send. Transfer your subscription to NEXT Life Sciences to receive updates on clinical trials:

[Yes, I want to continue receiving updates](#)



L.R. Fox, CEO of NEXT Life Sciences, met with Elaine Lissner, Founder and Trustee of the Parsemus Foundation, to discuss progress on the Plan A male contraceptive, which utilizes Vasalgel.

Two years ago this month, we announced that NEXT Life Sciences was taking over development of the Vasalgel male contraceptive. Today we're sending you our final Vasalgel Update — and it's simply a reminder that if you'd like to continue to receive updates about Vasalgel and the Plan A birth control method, you must subscribe here:

[Yes, I want to continue receiving updates](#)

Copyright © 2024 Parsemus Foundation, All rights reserved.

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).